WasThe proportion of infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy reporting adverse events (AEs) from birth through 1 month of age, The proportion of infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy reporting medically attended events (MAAEs) from birth through 6 months of age, The proportion of infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy reporting serious adverse events (SAEs) from birth through end of the study, The proportion of maternal participants reporting adverse events (AEs) through 1 month following study intervention, The proportion of maternal participants reporting medically attended adverse events (MAAEs) through 6 months after delivery, The proportion of maternal participants reporting prespecified local reactions within 7 days following study intervention, The proportion of maternal participants reporting prespecified systemic events within 7 days following study intervention, The proportion of maternal participants reporting serious adverse events (SAEs) through 6 months after delivery, To evaluate the aggregate predicted VE combining all 6 serotypes in GBS6 to provide protection from invasive GBS early onset disease based on serotype specific anti-CPS IgG concentrations measured in infants at birth., To evaluate the aggregate predicted VE combining all 6 serotypes in GBS6 to provide protection from invasive GBS late onset disease based on serotype specific anti-CPS IgG concentrations measured in infants at birth., To measure the relative risk reduction in the proportion of infant participants at birth with GBS serotype-specific IgG antibody concentrations below predefined serotype-specific GBS early onset disease thresholds in the GBS6 group to the placebo group, To measure the relative risk reduction in the proportion of infant participants at birth with GBS serotype-specific IgG antibody concentrations below predefined serotype-specific GBS late onset disease thresholds in the GBS6 group to the placebo group
NowThe proportion of infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy reporting adverse events (AEs) from birth through 1 month of age, The proportion of infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy reporting adverse events of special interest (AESIs) from birth through end of study, The proportion of infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy reporting medically attended adverse events (MAAEs) from birth through 6 months of age, The proportion of infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy reporting serious adverse events (SAEs) from birth through end of the study, The proportion of maternal participants reporting adverse events (AEs) through 1 month following study intervention, The proportion of maternal participants reporting adverse events of special interest (AESIs) through 6 months after delivery., The proportion of maternal participants reporting medically attended adverse events (MAAEs) through 6 months after delivery, The proportion of maternal participants reporting prespecified local reactions within 7 days following study intervention, The proportion of maternal participants reporting prespecified systemic events within 7 days following study intervention, The proportion of maternal participants reporting serious adverse events (SAEs) through 6 months after delivery, To evaluate the aggregate predicted VE combining all 6 serotypes in GBS6 to provide protection from invasive GBS early onset disease based on serotype specific anti-CPS IgG concentrations measured in infants at birth., To evaluate the aggregate predicted VE combining all 6 serotypes in GBS6 to provide protection from invasive GBS late onset disease based on serotype specific anti-CPS IgG concentrations measured in infants at birth., To measure the relative risk reduction in the proportion of infant participants at birth with GBS serotype-specific IgG antibody concentrations below predefined serotype-specific GBS early onset disease thresholds in the GBS6 group to the placebo group, To measure the relative risk reduction in the proportion of infant participants at birth with GBS serotype-specific IgG antibody concentrations below predefined serotype-specific GBS late onset disease thresholds in the GBS6 group to the placebo group